PHASE ONE Funds Children’s Hospital Los Angeles Study of Novel Treatment for Osteosarcoma

PHASE ONE Foundation has awarded Children’s Hospital Los Angeles $350,000 to partially fund a Phase II study investigating a new treatment option for patients with refractory or recurrent osteosarcoma.

Osteosarcoma is the most common malignant bone tumor in children, adolescents, and young adults. Despite current treatments including intensive multi-agent cytotoxic chemotherapy and surgery, about 40% of patients with localized disease and over 70% of those with metastatic disease at diagnosis, will not survive. Although treatment options do exist for osteosarcoma, the current regimen has long-term side effects and co-morbidities, leaving young survivors with quality-of-life issues. The goal of this study is to provide safer and more effective treatment options for this aggressive disease for children, adolescents and young adults.

PHASE ONE Foundation is one of many philanthropic organizations funding this important study to be conducted at Children’s Hospital Los Angeles (CHLA). The study will be led by Principal Investigators, Dr. Fariba Navid, Assistant Director of the Clinical Trials Program and COG Phase I & Pilot Consortium and Dr. Leo Mascarenhas, Deputy Director of the Cancer and Blood Disease Institute, both of CHLA.

The researchers will combine Regorafenib, a drug that has proved to be beneficial in osteosarcoma patients, with an immunotherapy called Nivolumab. They believe this combination will allow for a more effective therapy that will yield promising anti-tumor activity in osteosarcoma patients. The primary goal of the trial is to determine whether this novel combination is more effective than using Regorafenib alone.

This multicenter study is being led by the team at CHLA in coordination with the Sarcoma Alliance for Research through Collaboration (SARC).

PHASE ONE is proud to support this innovative study at CHLA, which helps fulfill their mission to fund ground-breaking clinical cancer research. Research like this wouldn’t be possible without the many generous donors and supporters of the PHASE ONE Foundation. Visit www.phaseonefoundation.org for updates on this grant and to learn more about clinical trials.